

1 **Making a Case for an Autism-Specific Multimorbidity Index: A Comparative Cohort Study**

2 Dr Filip Sosenko^{1*}, Dewy Nijhof^{1*}, Dr Laura McKernan Ward², Prof. Deborah Cairns¹, Dr Laura
3 Hughes¹, Dr Ewelina Rydzeswka³, on behalf of the CVD-COVID-UK/COVID-IMPACT Consortium

4 ¹University of Glasgow, School of Mental Health and Wellbeing

5 ²University of Dundee, Health Informatics Centre

6 ³University of Edinburgh, School of Health in Social Science

7

8 **Joint first authors*

9 *Corresponding author: Dr Filip Sosenko, filip.sosenko@glasgow.ac.uk*

10

11 **Keywords:** Autism Spectrum Disorder, Multimorbidity, Multimorbidity Index, COVID-19,
12 Mortality, Long-term Conditions

13

14 **Abstract**

15 Autistic people experience challenges in healthcare, including disparities in health outcomes
16 and multimorbidity patterns distinct from the general population. This study investigated the
17 efficacy of existing multimorbidity indices in predicting COVID-19 mortality among autistic
18 adults and proposes a bespoke index, the ASD-MI, tailored to their specific health profile.
19 Using data from the CVD-COVID-UK/COVID-IMPACT Consortium, encompassing England's
20 entire population, we identified 1,027 autistic adults hospitalized for COVID-19, among whom
21 62 died due to the virus. Employing logistic regression with 5-fold cross-validation, we selected
22 diabetes, coronary heart disease, and thyroid disorders as predictors for the ASD-MI,
23 outperforming the Quan Index, a general population-based measure, with an AUC of 0.872
24 versus 0.828, respectively. Notably, the ASD-MI exhibited better model fit (pseudo-R² 0.25)
25 compared to the Quan Index (pseudo-R² 0.20). These findings underscore the need for
26 tailored indices in predicting mortality risks among autistic individuals. However, caution is
27 warranted in interpreting results, given the limited understanding of morbidity burden in this
28 population. Further research is needed to refine autism-specific indices and elucidate the
29 complex interplay between long-term conditions and mortality risk, informing targeted
30 interventions to address health disparities in autistic adults. This study highlights the

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 importance of developing healthcare tools tailored to the unique needs of neurodivergent
32 populations to improve health outcomes and reduce disparities.

33 **Introduction**

34 Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterised mainly by
35 differences in social communication and interaction, and repetitive and restrictive
36 behaviours, including differences in sensory preferences (1). Autistic people are estimated to
37 account for 0.6 to 1.0% of the global population (2–4). They experience substantial health
38 inequalities, including multimorbidity (5,6), defined as the presence of at least two long-term
39 conditions (LTCs) (7). ASD has been proposed as a potential risk factor for the development of
40 COVID-19 infections due to a number of factors including; experiencing difficulties in
41 maintaining social distancing (8), and use of atypical antipsychotics, such as risperidone,
42 frequently prescribed to individuals with ASD (9), which has been shown to disrupt immune
43 responses (10), and therefore increase the risk of COVID-19 infection and mortality.

44 Autistic people have a different pattern of multimorbidity compared to the general
45 population (11,12) which can result in premature mortality (13,14). What is more, literature
46 suggests that autistic people are likely to experience poor physical health (12,15), high
47 prevalence of multimorbidity (16), and premature mortality (13,17,18). This highlights the
48 necessity of capturing the full burden of multimorbidity to detect poor health and provide
49 suitable care.

50 Multimorbidity indices, which are used to predict the prognosis of patients based on their
51 medical history or to measure the comorbidity burden, are currently based on the general
52 population (19–21), and may not be applicable to the population with ASD. Multimorbidity
53 indices use previous and current diagnoses as predictors for the outcome of interest, such as
54 quality of life, hospital admissions, healthcare use, and mortality (22,23). Alternatively, the
55 index is used to control for long-term conditions or multimorbidity while studying other
56 associations.

57 A variety of multimorbidity indices exist, and characteristics amongst these instruments vary
58 in terms of included LTCs, weighting of LTCs and even outcome measures (22). The most used
59 and well-known index is the Charlson Comorbidity Index (CCI) which uses scores for 17 LTCs
60 to predict the ten-year risk of death within one year after hospital admission (19). Since its

61 conception, several modifications of the CCI have been created, ranging in which LTCs are
62 included, total number of diseases included, weights of individual LTCs and overall score
63 construction (22). The most well-known modifications include the Elixhauser Index (including
64 30 – or, for some variants, 31 – LTCs) (20) and the van Walraven (VW) variant of the Elixhauser
65 Index, which includes a weighted summary score for streamlined use, based on the 30 LTCs
66 from the Elixhauser Index (21). The Quan Index is a relatively recent mortality prediction tool
67 utilized in healthcare settings, primarily focused on in-hospital mortality risk assessment.
68 Unlike the Charlson Index, which includes 17 Long-Term Conditions (LTCs), the Quan Index
69 streamlines the assessment by incorporating only 12 LTCs (24). These LTCs are determined
70 based on International Classification of Diseases, 10th Revision (ICD-10) codes. One notable
71 feature of the Quan Index is its utilization of up-to-date population health data from six
72 different countries to inform the construction of weights assigned to each LTC, enhancing the
73 predictive accuracy of the index (24).

74 Most indices use scores to estimate prognosis, with higher scores usually being indicative of
75 more severe risk of death. These scores are usually additive, where the presence of multiple
76 LTCs will lead to a higher score. Scores are based on weights for each condition, which usually
77 are derived from the modelling of the risk, in which the weight quantifies their contribution
78 towards the outcome. The long history of development and validation of these instruments
79 has resulted in establishing strong evidence of associations between multimorbidity and
80 mortality risk, decline in physical and mental functioning, and quality of life (22,23). However,
81 less research has focused on the selection criteria for inclusion of LTCs and most indices are
82 constructed for the general population (22).

83 As common physical and mental LTCs differ in the population with ASD compared from those
84 in the general population (13,25,26), this may be of importance. For example, autistic people
85 have a high burden of mental health conditions such as anxiety, depression and schizophrenia
86 (14,27). Autistic people are also more likely to experience co-occurring physical conditions,
87 such as epilepsy, autoimmune disorders and obesity (14,27). Therefore, the effectiveness and
88 sensitivity of the established multimorbidity indices for the prediction of health outcomes in
89 the autistic population and subsequent treatment based on those predictions warrants an
90 investigation into their validity. Indeed, studies examining the association between LTCs and
91 mortality in autistic people make use of established multimorbidity indices, such as the CCI,

92 but include LTCs known to be prevalent in the autistic population (14,27). These studies found
93 that the included LTCs, such as epilepsy, mental health conditions (e.g., bipolar disorder,
94 schizophrenia, major depressive disorder) or intellectual disabilities carried higher risk of
95 death in the autistic population (14,27). This suggests that traditional indices may not
96 accurately reflect the health profile or capture the full extent of multimorbidity and its
97 concurrent risk for the autistic population.

98 To our knowledge, there has been no previous research into the effectiveness of using existing
99 multimorbidity indices to investigate health outcomes in autistic people nor does a
100 multimorbidity index specifically tailored for autistic populations exist. As such, the current
101 study aims to address this gap in the existing literature by investigating the effectiveness and
102 sensitivity of an established multimorbidity index compared to a specifically tailored index,
103 hereafter called Autism Spectrum Disorder Multimorbidity Index (ASD-MI), in predicting
104 COVID-19 mortality within the autistic population. This study represents a supplementary
105 analysis derived from a broader investigation examining COVID-19 outcomes in autistic adults
106 (28,29). As such, the study design employed a convenience sampling approach, necessitated
107 by the availability of relevant data sources.

108 **Methods**

109 ***Data sources***

110 This was part of a larger cross-sectional study using a whole-country population covering
111 England (30,31). It was conducted on behalf of, and accessed data made available in NHS
112 England's Secure Data Environment service for England, the [CVD-COVID-UK/COVID-IMPACT](#)
113 [Consortium](#) (coordinated by the BHF Data Science Centre). The datasets used for the current
114 study were Hospital Episode Statistics (HES), COVID-19 Hospitalisation in England Surveillance
115 System (CHESS), Second Generation Surveillance System (SGSS), General Practice Extraction
116 Service (GPES) Data for Pandemic Planning and Research (GDPPR) and Civil Registry Deaths
117 from the Office for National Statistics (ONS-D). All but the last of these datasets are updated
118 through the National Health Service (NHS) and processed by NHS England who then opens up
119 the data for secondary use. The ONS-D dataset is updated through the ONS. Data from 1
120 March 2020 up to and including 31 December 2021 was used. Data linkage was conducted
121 using an anonymised version of the NHS number (a ten-digit number used as a unique

122 identifier within the UK NHS to identify patients). Ethical approval was obtained from the CVD-
123 COVID-UK/COVID-IMPACT Consortium and the University of Glasgow Ethics Committee.

124

125 Autistic people were identified using SNOMED concepts sourced from the GPPR and HES
126 'Autism Diagnosis Codes' cluster¹ (cluster AUTISM COD version 2021/12/21). With regards to
127 the long-term conditions considered as 'candidates' for the ASD-MI, thirty-five long-term
128 conditions common to the UK population were identified (32) (see Supplementary materials,
129 table 1). One-year look-back window (in HES) was used to identify patients with a given
130 condition, counting from the date of COVID-19 admission.

131

132 Demographic (age, sex, ethnicity, Index of Multiple Deprivation (IMD)) and LTCs were
133 explored using percentages of total autistic population. IMD decile is a measure used in the
134 United Kingdom to assess relative deprivation across different areas or regions. The IMD ranks
135 from 1 (most deprived) to 10 (least deprived) based on several indicators of deprivation, such
136 as income, employment, education, health, crime, and living environment. In our analyses,
137 instead of having 10 distinct deciles, the IMD rankings were grouped into 5 categories, each
138 representing a range of deprivation levels. This grouping simplifies the interpretation of
139 deprivation levels and facilitates comparisons between areas.

140 The decision to compare our ASD-MI to the Quan Index rather than the Charlson Index was
141 carefully considered. Firstly, our study was constrained by the requirement to use ICD-10 code
142 mapping, which is a feature supported by the Quan Index but not the Charlson Index (24).
143 Furthermore, the Quan Index's more recent update and incorporation of contemporary
144 population health data from six countries provided a distinct advantage (24). This up-to-date
145 information enhances the predictive capabilities of the Quan Index, aligning with our study's
146 objective of accurately predicting in-hospital mortality risk among autistic adults with COVID-
147 19. To predict in-hospital mortality, the Quan Index includes 12 LTCs instead of the original
148 17 used in the Charlson Index to construct weights (33) (see Supplementary materials, table

¹ Primary Care Domain Reference Set Portal. NHS Digital, <https://digital.nhs.uk/data-and-information/data-collections-and-data-sets/data-collections/quality-and-outcomes-framework-qof/quality-and-outcome-framework-qof-business-rules/primary-care-domain-reference-set-portal> (accessed 8 August 2023).

149 2). Again, a one-year look-back window in HES was used to calculate the patient's Quan Index
150 score.

151

152 **Population**

153 The study sample was drawn from a larger study sample that covered the whole population
154 of England who were alive on 1 January 2020 (31). Adults who had a primary care diagnosis
155 of autism and who were hospitalised for COVID-19 (defined as any CHES record, or a HES
156 record with an ICD-10 code of U07.1 or U07.2 recorded in any position on the admission
157 diagnosis). 'COVID-19 cause of death' was defined as a death that occurred within 28 days
158 from the first day of admission and where COVID-19 was mentioned on the death certificate
159 (either primary or other contributing causes using ICD-10 code U07.1 or U07.2). For the larger
160 study, the total sample with confirmed COVID-19 was 32,372 autistic adults (see Table 1). The
161 sample used to construct the multimorbidity index consisted of 1,027 autistic adults
162 hospitalised for COVID-19, of which 62 died due to COVID-19. Data up to 31 December 2021
163 was included.

164

165 **Data analysis**

166 All data analysis was conducted in Python 3.7 and SQL. The analysis was performed according
167 to a pre-specified analysis plan published on GitHub, along with the phenotyping and analysis
168 code (https://github.com/BHFDSC/CCU030_03).

169

170 In the first stage of data analysis, a forward variable selection procedure using logistic
171 regression with 5-fold cross-validation was used to identify which of the 35 long-term
172 conditions (see Supplementary materials, table 3) should be selected for the ASD-MI. Age was
173 included as an additional predictor, as per procedure in the development of the CCI (19). The
174 absence or presence of COVID-19 death was the outcome. Area Under the Curve (AUC) score
175 was used as the model evaluation metric. Predictor selection was stopped when the AUC
176 value of the model could not be further improved by at least 0.001. Once a final model was
177 arrived at, coefficients of the long-term conditions from that model were then used to
178 construct an ASD-MI Score for each condition.

179

180 Once the ASD-MI was ready, the second stage of data analysis commenced by assessing
181 predictive performance of a model with the Quan Index and a model with the ASD-MI through
182 5-fold cross validation with AUC as evaluation metric. The modelling employed logistic
183 regression with the absence or presence of COVID-19 death as the outcome. Age was again
184 included as a control variable.

185

186 **Results**

187 ***Demographics***

188 The results presented in Table 1 provide a comprehensive overview of the demographic and
189 health characteristics of autistic adults hospitalised for COVID-19, categorised based on
190 subsequent COVID-19 mortality outcomes. Among the total cohort of 1,030 hospitalised
191 adults, 60 individuals died due to COVID-19, while 965 individuals did not. The median age of
192 those who died from COVID-19 was notably higher at 63.4 years (interquartile range: 48.9 to
193 75.2) compared to survivors, with a median age of 31.1 years (interquartile range: 23.6 to 50.0).
194 A higher proportion of females were observed among survivors (40.6%) compared to those
195 who died from COVID-19 (19.4%). Additionally, the mean IMD decile was similar between both
196 groups, indicating comparable levels of deprivation. Regarding LTCs, individuals who
197 subsequently died from COVID-19 had a higher mean count of LTCs (11.0) compared to
198 survivors (7.4). Furthermore, several LTCs demonstrated notable differences in prevalence
199 between the two groups, with higher proportions observed among individuals who died from
200 COVID-19, although these results should be interpreted with caution due to small numbers.

201

202 ***Predictor Selection for the ASD-MI***

203 By employing a forward variable selection procedure using logistic regression with 5-fold
204 cross-validation, we systematically evaluated the predictive capabilities of 35 long-term
205 conditions (LTCs) in relation to COVID-19 mortality risk among autistic adults. This approach
206 allowed us to identify the most influential LTCs associated with the outcome of interest. By
207 iteratively assessing the model's performance using the Area Under the Curve (AUC) score
208 as the evaluation metric, we identified three LTCs that consistently demonstrated the
209 highest predictive power. The selected variables for the ASD-MI were diabetes, coronary
210 heart disease and thyroid disorders. These LTCs emerged as significant contributors to the

211 ASD-MI, reflecting their strong association with COVID-19 mortality risk in this population.
212 This process ensured that the selected LTCs were robust indicators of mortality risk,
213 disregarding indicators that did not add to the predictive power of the model. Table 2 shows
214 the coefficients of the LTCs included in the ASD-MI and their corresponding Odds Ratios.
215 Using the coefficients from the model, the formula for the Multimorbidity Index (MI) was:

216
217
$$MI = 1.21 * DIA + 0.71 * CHD + 0.67 * THY$$

218 Where DIA refers to diabetes, CHD to coronary heart disease, and THY to thyroid disorders.
219 Each are multiplied by their respective coefficients from the model.

220

221 ***Comparative Predictive Performance of the two models***

222 The logistic model using the ASD-MI had a higher AUC value of 0.872 than the model using
223 the Quan Index, which had an AUC value of 0.828. Table 2 shows the regression results for
224 both models using the Quan Index and the ASD-MI. Further, model fit is better for the model
225 using the ASD-MI (pseudo-R² 0.25) than for the model using Quan Index (pseudo-R² 0.20).

226

227 **Discussion**

228 This feasibility study aimed to investigate whether there is a need for a specially tailored
229 multimorbidity index to predict COVID-19-related mortality in autistic adults. Using LTCs that
230 more accurately describe the health profile of the autistic population, the results show that
231 our ASD-MI is moderately better at predicting the risk of COVID-19 death amongst autistic
232 adults than a general population-based index. This study is a case in point to show the
233 potential for development for general poor health outcomes specific to autistic adults,
234 especially if trained for mortality outside of a COVID-19 context.

235 While our results suggest a better prediction of COVID-19 mortality in autistic adults using the
236 three predictors of diabetes, coronary heart disease and thyroid dysfunction, caution should
237 be used when interpreting these results. We emphasise that further research is needed to
238 accurately predict all-cause mortality due to the known associations of these three conditions
239 with COVID-19 (34–36). Current evidence on all-cause mortality in autistic individuals points
240 mainly to external causes, such as suicide, and neurological disorders (13,14) It could well be

241 that the current study's formulation of the ASD-MI does not generalise well to all-cause
242 mortality in autistic adults. Furthermore, relatively little is known about the morbidity burden
243 of coronary heart disease and thyroid disorders in autistic individuals. This further emphasises
244 the importance of studying the general health profile of autistic individuals and how a
245 specifically tailored multimorbidity index could help in finding target LTCs for future research.

246 One aspect of the study that needs to be emphasised is that our ASD-MI, similar to the original
247 CCI and Quan Index, was developed purely for the purpose of prediction. Accordingly,
248 predictive power was the only criterion for selecting one model over another. Therefore, like
249 the creators of earlier indices we did not aim to explain why selected LTCs were better
250 predictors than LTCs that were ruled out. And we do not seek to justify LTC selection on
251 grounds of existing knowledge and risk factors for COVID-19 mortality (see (37) for further
252 discussion).

253 The current study did find significant differences in the predictive value of our ASD-MI and a
254 standard index, despite limiting the data to COVID-19-related deaths in the peak of the global
255 pandemic in England. Future research expanding this methodology to all-cause mortality
256 using a larger window of time may yield larger sample sizes and more generalisable results.
257 This would arguably help improve predicting mortality for autistic adults in healthcare
258 settings. Further, it would help elucidate the multimorbidity profile of autistic adults by virtue
259 of its selection criteria for included LTCs. Furthermore, these findings and future exploration
260 of all-cause mortality may highlight LTCs and combinations of LTCs that are of most urgency
261 to investigate in order to address increased mortality in autistic adults.

262 **Strengths and limitations**

263 This study has several strengths. It is the first study to investigate and construct a
264 multimorbidity index specifically aimed at autistic adults. Foremost, the utilization of a whole-
265 country population encompassing both autistic individuals and the general population
266 ensures a comprehensive and representative sample, effectively mitigating potential
267 sampling biases. Additionally, the study leverages validated datasets, further fortifying the
268 credibility of the results. Furthermore, the inclusion criteria for autism diagnosis are
269 meticulously defined based on clinical diagnoses, incorporating a wide range of older and
270 newer diagnostic codes pertinent to autism. This comprehensive approach enables the study
271 to capture a diverse spectrum of individuals on the autism spectrum, thereby offering a more

272 nuanced and accurate representation of the autistic population in England. Overall, these
273 strengths collectively underscore the study's capacity to provide valuable insights into the
274 health profiles and multimorbidity patterns among autistic individuals, contributing to a
275 deeper understanding of their healthcare needs.

276

277 One potential limitation stems from the sample characteristics. Given the focus on evaluating
278 the multimorbidity index within the context of COVID-19, the sample composition may be
279 skewed, particularly in terms of age and sex distribution. Notably, while older age has been
280 associated with increased COVID-19 mortality risk, the autistic sample in this study tended to
281 be younger due to the higher rates of autism diagnosis in children and young individuals.
282 Moreover, the male predominance in both COVID-19 cases and autism diagnoses introduces
283 further complexity, potentially influencing the observed outcomes. These inherent biases
284 may limit the extrapolation of study findings to broader populations. However, despite these
285 limitations, this study contributes valuable insights into the health profiles of autistic
286 individuals and underscores the importance of developing tailored tools to address their
287 unique healthcare needs, thereby highlighting avenues for further research and exploration
288 in this area.

289 Another potential limitation is the possible introduction of an inherent bias in the data due to
290 the use of several code mappings to accommodate information coding in the different types
291 of datasets and analysis tools used which originates from data linkage using multiple systems
292 that use different codes within their electronic health records.

293 Further, while the follow-up time in the CCI and Quan Index is one year after admission, the
294 current study used a follow-up time of 28 days in order to be consistent with the official
295 definition of COVID-19 death.

296 **Conclusion**

297 This point in case study demonstrated that the use of our ASD-MI for the adult autistic
298 population provides more accurate predictions of COVID-19 mortality in this population than
299 a multimorbidity index based on the general population. It shows that application of the ASD-
300 MI trained on all-cause mortality the autistic population may be more appropriate than the

301 use of multimorbidity indices based on the general population and could be used to elucidate
302 key differences between the health profiles of autistic and non-autistic people.

303

304 **Declarations**

305 **Ethics approval and consent to participate**

306 The North East – Newcastle and North Tyneside 2 research ethics committee provided ethical
307 approval for the CVD-COVID-UK/COVID-IMPACT research programme (REC No 20/NE/0161)
308 to access, within secure trusted research environments, unconsented, whole-population, de-
309 identified data from electronic health records collected as part of patients' routine
310 healthcare. The need for informed consent was waived by the North East – Newcastle and
311 North Tyneside 2 research ethics committee. All methods were carried out in accordance with
312 relevant guidelines and regulations.

313 **Availability of data and materials**

314 The data used in this study are available in NHS England's Secure Data Environment (SDE)
315 service for England, but as restrictions apply they are not publicly available
316 (<https://digital.nhs.uk/services/secure-data-environment-service>).

317 The CVD-COVID-UK/COVID-IMPACT programme led by the BHF Data Science Centre
318 (<https://bhfdatasciencecentre.org/>) received approval to access data in NHS England's SDE
319 service for England from the Independent Group Advising on the Release of Data (IGARD)
320 ([https://digital.nhs.uk/about-nhs-digital/corporate-information-and-](https://digital.nhs.uk/about-nhs-digital/corporate-information-and-documents/independent-group-advising-on-the-release-of-data)
321 [documents/independent-group-advising-on-the-release-of-data](https://digital.nhs.uk/about-nhs-digital/corporate-information-and-documents/independent-group-advising-on-the-release-of-data)) via an application made in
322 the Data Access Request Service (DARS) Online system (ref. DARS-NIC-381078-Y9C5K)
323 ([https://digital.nhs.uk/services/data-access-request-service-dars/dars-products-and-](https://digital.nhs.uk/services/data-access-request-service-dars/dars-products-and-services)
324 [services](https://digital.nhs.uk/services/data-access-request-service-dars/dars-products-and-services)).

325 The CVD-COVID-UK/COVID-IMPACT Approvals & Oversight Board
326 (<https://bhfdatasciencecentre.org/areas/cvd-covid-uk-covid-impact/>) subsequently granted
327 approval to this project to access the data within NHS England's SDE service for England. The
328 de-identified data used in this study were made available to accredited researchers only.
329 Those wishing to gain access to the data should contact bhfdsc@hdruk.ac.uk in the first
330 instance.

331 **Funding**

332 The British Heart Foundation Data Science Centre (grant No SP/19/3/34678, awarded to
333 Health Data Research (HDR) UK) funded co-development (with NHS England) of the Secure
334 Data Environment service for England, provision of linked datasets, data access, user software
335 licences, computational usage, and data management and wrangling support, with additional
336 contributions from the HDR UK Data and Connectivity component of the UK Government
337 Chief Scientific Adviser's National Core Studies programme to coordinate national COVID-19
338 priority research. Consortium partner organisations funded the time of contributing data
339 analysts, biostatisticians, epidemiologists, and clinicians.

340 The associated costs of accessing data in NHS England's Secure Data Environment service for
341 England, for analysts working on this study, were funded by the Data and Connectivity
342 National Core Study, led by Health Data Research UK in partnership with the Office for
343 National Statistics, which is funded by UK Research and Innovation (grant ref: MC_PC_20058).

344 The Baily Thomas Charitable Fund funded staff (FS) time on this project.

345 **Acknowledgements**

346 This work is carried out with the support of the BHF Data Science Centre led by HDR UK (BHF
347 Grant no. SP/19/3/34678). This study makes use of de-identified data held in NHS England's
348 Secure Data Environment service for England and made available via the BHF Data Science
349 Centre's CVD-COVID-UK/COVID-IMPACT consortium. This work uses data provided by
350 patients and collected by the NHS as part of their care and support. We would also like to
351 acknowledge all data providers who make health relevant data available for research.

352 The authors would like to thank The Baily Thomas Charitable Fund for funding staff costs on
353 this study.

354 **Data Availability Statement**

355 For the purpose of open access, the authors have applied a Creative Commons Attribution
356 (CC BY) licence to any Author Accepted Manuscript version arising from this submission.

357

358 **References**

359 1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th
360 ed. Arlington: American Psychiatric Publishing; 2013.

- 361 2. Zeidan J, Fombonne E, Scora J, Ibrahim A, Durkin MS, Saxena S, et al. Global prevalence of
362 autism: A systematic review update. *Autism Research*. 2022 May 1;15(5):778–90.
- 363 3. Salari N, Rasoulpoor S, Rasoulpoor S, Shohaimi S, Jafarpour S, Abdoli N, et al. The global
364 prevalence of autism spectrum disorder: a comprehensive systematic review and meta-
365 analysis. *Italian Journal of Pediatrics* 2022 48:1. 2022 Jul 8;48(1):1–16.
- 366 4. Talantseva OI, Romanova RS, Shurdova EM, Dolgorukova TA, Sologub PS, Titova OS, et al. The
367 global prevalence of autism spectrum disorder: A three-level meta-analysis. *Frontiers in*
368 *Psychiatry*. 2023 Feb 9;14:1071181.
- 369 5. Bishop-Fitzpatrick L, Rubenstein E. The physical and mental health of middle aged and older
370 adults on the autism spectrum and the impact of intellectual disability. *Research in Autism*
371 *Spectrum Disorders*. 2019 Jul 1;63:34–41.
- 372 6. Croen LA, Zerbo O, Qian Y, Massolo ML, Rich S, Sidney S, et al. The health status of adults on
373 the autism spectrum. <http://dx.doi.org/10.1177/1362361315577517>. 2015 Apr 24;19(7):814–
374 23.
- 375 7. NICE | The National Institute for Health and Care Excellence. Overview | Multimorbidity:
376 clinical assessment and management | Guidance | NICE [Internet]. 2016 [cited 2023 Jul 3].
377 Available from: <https://www.nice.org.uk/guidance/ng56>
- 378 8. Brondino N, Bertoglio F, Forneris F, Faravelli S, Borghesi A, Damiani S, et al. A Pilot Study on
379 Covid and Autism: Prevalence, Clinical Presentation and Vaccine Side Effects. *Brain Sciences*
380 2021, Vol 11, Page 860. 2021 Jun 28;11(7):860.
- 381 9. Fusar-Poli L, Brondino N, Rocchetti M, Petrosino B, Arillotta D, Damiani S, et al. Prevalence
382 and predictors of psychotropic medication use in adolescents and adults with autism
383 spectrum disorder in Italy: A cross-sectional study. *Psychiatry Research*. 2019 Jun 1;276:203–
384 9.
- 385 10. May M, Slitzky M, Rostama B, Barlow D, Houseknecht KL. Antipsychotic-induced immune
386 dysfunction: A consideration for COVID-19 risk. *Brain, Behavior, & Immunity - Health*. 2020 Jul
387 1;6:100097.
- 388 11. Hossain MM, Khan N, Sultana A, Ma P, McKyer ELJ, Ahmed HU, et al. Prevalence of comorbid
389 psychiatric disorders among people with autism spectrum disorder: An umbrella review of
390 systematic reviews and meta-analyses. Vol. 287, *Psychiatry Research*. 2020.
- 391 12. Ryzewska E, Dunn K, Cooper SA. Umbrella systematic review of systematic reviews and
392 meta-analyses on comorbid physical conditions in people with autism spectrum disorder. *The*
393 *British journal of psychiatry : the journal of mental science*. 2021 Jan 1;218(1):10–9.
- 394 13. Forsyth L, Mcorley M, Ryzewska E. All-cause and cause-specific mortality in people with
395 autism spectrum disorder: A systematic review. *Research in Autism Spectrum Disorders*.
396 2023;105:102165.
- 397 14. Tsai SJ, Chang WH, Cheng CM, Liang CS, Bai YM, Hsu JW, et al. All-cause mortality and suicide
398 mortality in autistic individuals: An entire population longitudinal study in Taiwan. *Autism*.
399 2023 May 10;

- 400 15. Rydzewska E, Hughes-McCormack LA, Gillberg C, Henderson A, MacIntyre C, Rintoul J, et al.
401 General health of adults with autism spectrum disorders – A whole country population cross-
402 sectional study. *Research in Autism Spectrum Disorders*. 2019 Apr 1;60:59–66.
- 403 16. British Medical Association. Recognising the importance of physical health in mental health
404 and intellectual disability: achieving parity of outcomes [Internet]. 2014 [cited 2023 Jul 3].
405 Available from: [https://www.scie-socialcareonline.org.uk/recognising-the-importance-of-](https://www.scie-socialcareonline.org.uk/recognising-the-importance-of-physical-health-in-mental-health-and-intellectual-disability-achieving-parity-of-outcomes/r/a11G0000004Gp6QIAS)
406 [physical-health-in-mental-health-and-intellectual-disability-achieving-parity-of-](https://www.scie-socialcareonline.org.uk/recognising-the-importance-of-physical-health-in-mental-health-and-intellectual-disability-achieving-parity-of-outcomes/r/a11G0000004Gp6QIAS)
407 [outcomes/r/a11G0000004Gp6QIAS](https://www.scie-socialcareonline.org.uk/recognising-the-importance-of-physical-health-in-mental-health-and-intellectual-disability-achieving-parity-of-outcomes/r/a11G0000004Gp6QIAS)
- 408 17. Hirvikoski T, Mittendorfer-Rutz E, Boman M, Larsson H, Lichtenstein P, Bölte S. Premature
409 mortality in autism spectrum disorder. *The British Journal of Psychiatry*. 2016 Mar
410 1;208(3):232–8.
- 411 18. Catalá-López F, Hutton B, Page MJ, Driver JA, Ridao M, Alonso-Arroyo A, et al. Mortality in
412 Persons With Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder: A
413 Systematic Review and Meta-analysis. *JAMA Pediatrics*. 2022 Apr 1;176(4):e216401–e216401.
- 414 19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic
415 comorbidity in longitudinal studies: development and validation. *Journal of chronic diseases*.
416 1987;40(5):373–83.
- 417 20. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity Measures for Use with
418 Administrative Data. *Medical Care*. 1998;36(1):8–27.
- 419 21. Van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser
420 comorbidity measures into a point system for hospital death using administrative data.
421 *Medical care*. 2009 Jun;47(6):626–33.
- 422 22. Diederichs C, Berger K, Bartels DB. The Measurement of Multiple Chronic Diseases—A
423 Systematic Review on Existing Multimorbidity Indices. *The Journals of Gerontology: Series A*.
424 2011 Mar 1;66A(3):301–11.
- 425 23. Stirland LE, González-Saavedra L, Mullin DS, Ritchie CW, Muniz-Terrera G, Russ TC. Measuring
426 multimorbidity beyond counting diseases: systematic review of community and population
427 studies and guide to index choice. *BMJ*. 2020 Feb 18;368.
- 428 24. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and Validating the
429 Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts
430 Using Data From 6 Countries. *Am J Epidemiol* [Internet]. 2011 Mar 15 [cited 2023 Jul
431 3];173(6):676–82. Available from: <https://dx.doi.org/10.1093/aje/kwq433>
- 432 25. Hossain MM, Khan N, Sultana A, Ma P, McKyer ELJ, Ahmed HU, et al. Prevalence of comorbid
433 psychiatric disorders among people with autism spectrum disorder: An umbrella review of
434 systematic reviews and meta-analyses. *Psychiatry Research*. 2020 Mar 18;287:112922–
435 112922.
- 436 26. Rydzewska E, Dunn K, Cooper SA. Umbrella systematic review of systematic reviews and
437 meta-analyses on comorbid physical conditions in people with autism spectrum disorder. *The*
438 *British Journal of Psychiatry*. 2021 Jan 1;218(1):10–9.

- 439 27. Hwang YI (Jane), Srasuebkul P, Foley KR, Arnold S, Trollor JN. Mortality and cause of death of
440 Australians on the autism spectrum. *Autism research : official journal of the International*
441 *Society for Autism Research*. 2019 May 1;12(5):806–15.
- 442 28. Nijhof D, Sosenko F, MacKay D, Fleming M, Jani B, Pell J, et al. COVID-19 hospitalisations and
443 mortality in autistic people: A whole-country population study. Manuscript in preparation.
- 444 29. Sosenko F, Mackay D, Bhautesh DJ, Fleming M, Pell JP, Hatton C, et al. Understanding covid-
445 19 outcomes among people with Intellectual Disabilities in England. *BMC Public Health*.
446 2023;23(2099).
- 447 30. Sosenko F, Mackay D, Bhautesh DJ, Fleming M, Pell JP, Hatton C, et al. Understanding covid-
448 19 outcomes among people with Intellectual Disabilities in England. *BMC Public Health*.
- 449 31. Nijhof D, Sosenko F, MacKay D, Fleming M, Jani B, Pell J, et al. COVID-19 hospitalisations and
450 mortality in autistic people: A whole-country population study. Manuscript in preparation.
- 451 32. Cassell A, Edwards D, Harshfield A, Rhodes K, Brimicombe J, Payne R, et al. The epidemiology
452 of multimorbidity in primary care: a retrospective cohort study. *British Journal of General*
453 *Practice [Internet]*. 2018 Apr 1 [cited 2023 Jul 17];68(669):e245–51. Available from:
454 <https://bjgp.org/content/68/669/e245>
- 455 33. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and Validating the
456 Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts
457 Using Data From 6 Countries. *American Journal of Epidemiology*. 2011 Mar 15;173(6):676–82.
- 458 34. Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus
459 disease 2019 (Covid-19). *Diabetes/Metabolism Research and Reviews*. 2021 Feb
460 1;37(2):e3377.
- 461 35. Saha S, Al-Rifai RH, Saha S. Diabetes prevalence and mortality in COVID-19 patients: a
462 systematic review, meta-analysis, and meta-regression. 2021;
- 463 36. Zhang Y, Lin F, Tu W, Zhang J, Choudhry AA, Ahmed O, et al. Thyroid dysfunction may be
464 associated with poor outcomes in patients with COVID-19. *Molecular and Cellular*
465 *Endocrinology*. 2021 Feb 2;521:111097.
- 466 37. Shmueli G. To Explain or to Predict? <https://doi.org/10.1214/10-STS330>. 2010 Aug
467 1;25(3):289–310.

468

469

470 **Tables and figures**

471 *Table 1. Demographic and health characteristics of autistic adults hospitalised for COVID-19.*

	Covid-19 hospitalised adults who subsequently died from covid	Covid-19 hospitalised adults who subsequently did not die from covid	All covid-19 hospitalised adults
Total N (rounded)	60	965	1,030

Demographic information			
Age (median, IQR)	63.4 [48.9, 75.2]	31.1 [23.6, 50.0]	32.3 [24.0, 53.0]
Female (%)	19.4	40.6	39.3
IMD decile (mean)	4.8	4.6	4.6
Ethnicity (%)			
White	96.8	89.5	90.0
Asian	<10 CASES	3.2	3.1
Black	<10 CASES	2.7	2.5
Mixed	<10 CASES	2.7	2.6
Other	<10 CASES	1.5	1.4
Long-term conditions (%)			
Count of LTC (mean)	11.0	7.4	7.6
Alcohol problems	33.9	31.3	31.5
Anorexia or bulimia	<10 CASES	8.3	8.1
Anxiety & other neurotic	64.5	58.8	59.1
Asthma (currently treated)	27.4	27.9	27.9
Atrial fibrillation	33.9	10.4	11.8
Blindness and low vision	<10 CASES	6.7	7.0
Bronchiectasis	<10 CASES	<10 CASES	1.0
Cancer - [New]Diagnosis in last five years	40.3	18.0	19.4
Coronary heart disease	58.1	19.6	21.9
Chronic kidney disease	<10 CASES	1.2	1.2
Chronic Liver Disease and Viral Hepatitis	43.6	32.5	33.2
COPD	24.2	10.0	10.8
Dementia	51.6	52.5	52.5
Depression	38.7	43.0	42.8
Diabetes	85.5	37.8	40.7

Diverticular disease of intestine	43.6	25.6	26.7
Epilepsy (currently treated)	43.6	21.6	22.9
Heart failure	61.3	22.7	25.0
Hearing loss	<10 CASES	6.1	6.6
Hypertension	66.1	24.6	27.1
Inflammatory bowel disease	17.7	14.6	14.8
Irritable bowel syndrome	<10 CASES	9.3	9.4
Migraine	<10 CASES	5.5	5.7
Multiple sclerosis	<10 CASES	<10 CASES	<10 CASES
Peptic Ulcer Disease	<10 CASES	10.8	10.9
Parkinson's disease	<10 CASES	2.1	2.3
Prostate disorders	<10 CASES	6.8	7.2
Psychoactive substance misuse (not alcohol)	64.5	62.3	62.4
Psoriasis or eczema	<10 CASES	7.2	7.2
Peripheral vascular disease	22.6	7.2	8.1
Rheumatoid arthritis	22.6	15.2	15.7
Schizophrenia (and related non-organic psychosis) or bipolar disorder	83.9	78.9	79.2
Chronic sinusitis	<10 CASES	1.4	1.4
Stroke & transient ischaemic attack	62.9	51.1	51.8
Thyroid disorders	17.7	5.6	6.3

472

473

474 *Table 2. Logistic Regression results for the models using the Quan Index and the ASD-MI*

	Odds Ratio	95% Confidence Interval	P-value
Model with Quan Index			
Age at COVID	1.06	1.05, 1.08	0.000
Quan Index score	1.16	0.98, 1.37	0.081
Constant	0.00	0.00, 0.01	0.000

Model with ASD-MI			
Age (at COVID)	1.05	1.03, 1.07	0.000
Multimorbidity Index score	2.72	1.78, 4.14	0.000
Constant	0.00	0.00, 0.01	0.000

475

476

477